Objective: To estimate the prevalence of the metabolic syndrome in the Netherlands in two populations in the age category 28-59 years and to compare this with the prevalence of hypercholesterolaemia in these populations.
Design: Descriptive.
Method: Data from two Dutch population based studies were used: the 'Monitoring risicofactoren en gezondheid Nederland' (MORGEN) study ['Monitoring risk factors and health in the Netherlands' study] (1993-1995) and the 'Prevention of renal and vascular end-stage disease' (PREVEND) study (1998-1999). Subjects were identified as having the metabolic syndrome when they had at least three of the following five criteria according to the guideline of the 'National cholesterol education programme', 'Adult treatment panel III' (NCEP-2001): hyperglycaemia, low HDL-cholesterol level, hypertriglyceridaemia, hypertension or abdominal obesity. Final estimates were weighed according to the age- and sex distribution of the Dutch population during these survey years based on figures of the Dutch Central Bureau of Statistics.
Results: On average, the prevalence of the metabolic syndrome was 14%, 19% in men and 12% in women in the MORGEN study, and 16% and 10% in men and women in the PREVEND study. The prevalence in subjects below 40 was 12% for men and 5% for women. The prevalence increased considerably with age. Among subjects with both abdominal obesity and hypertension the prevalence was 68%. Among subjects with 'hypertriglyceridaemic waist' the prevalence was 94%. The prevalence of the metabolic syndrome showed little overlap with the prevalence of hypercholesterolaemia (> or = 6.5 mmol/l). In total, 26% of the subjects had either the metabolic syndrome or high total cholesterol levels.
Conclusion: Approximately 1 million Dutch adults below 60 years of age had the metabolic syndrome in the 1990's. Based on the total prevalence of the metabolic syndrome and hypercholesterolaemia, one quarter of the Dutch population younger then 60 runs an increased risk of cardiovascular disease and type 2 diabetes mellitus.
Download full-text PDF |
Source |
---|
Rev Col Bras Cir
January 2025
- Universidade Federal do Estado do Rio de Janeiro, Departamento de Cirurgia Geral - Serviço de Cirurgia Oncológica HUGG/EBSERH - Rio de Janeiro - RJ - Brasil.
Introduction: Advances in imaging methods have led to an increasingly frequent diagnosis of adrenal gland lesions as incidental findings. Despite progress in this field, there is still limited information regarding the epidemiology of the clinical and metabolic profile of patients with adrenal incidentaloma (AI). The objective is analyze the epidemiology of adrenal tumors at Gaffrée e Guinle University Hospital (HUGG) and compare it with data from the literature.
View Article and Find Full Text PDFRev Paul Pediatr
January 2025
Universidade Federal do Paraná, Curitiba, PR, Brazil.
Objective: To investigate the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) and gallbladder abnormalities in a sample of people with Down syndrome in Brazil.
Methods: This is a retrospective study using medical charts involving Down syndrome patients, diagnosed by karyotype, aged over 5 years, who underwent abdominal ultrasound and were monitored by the same professional in a clinic in Curitiba, Brazil. Data spanned January 1995 to September 2023; all cases with no use of alcohol or hepatotoxic medications.
Endocrine
January 2025
Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Purpose: Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of cardiometabolic diseases. The prevalence of MetS and individual components across pregnancy has not been reviewed in the literature. This research was conducted to identify the prevalence of MetS and its components among pregnant women.
View Article and Find Full Text PDFJ Investig Med High Impact Case Rep
January 2025
Faculty of Medicine and Health Sciences, Palestine Polytechnic University, Hebron, Palestine.
Rafiq syndrome, MAN1B1-CDG, was described in 2010 and associated with genetic mutation in MAN1B1 gene in 2011. The disorder follows an autosomal recessive pattern of inheritance and typically presents with specific facial dysmorphism, intellectual disability, developmental delay, obesity, and hypotonia. The syndrome belongs to a group of metabolic disorders called Congenital Glycosylation Disorders (CGD).
View Article and Find Full Text PDFFront Pediatr
January 2025
Department of Urology, The Affiliated Children's Hospital of Xiangya School of Medicine, Central South University (Hunan Children's Hospital), Changsha, China.
Objective: This study aimed to systematically evaluate the safety of cyclosporine (CsA) and tacrolimus (TAC) in pediatric nephrotic syndrome (NS) patients using real-world data from the FDA Adverse Event Reporting System (FAERS).
Methods: We analyzed adverse event (AE) reports from the FAERS database between Q4 2003 and Q2 2024, focusing on AEs associated with CsA and TAC in NS patients aged 18 years and younger. We employed three signal detection methods-Proportional Reporting Ratio (PRR), Relative Reporting Ratio (RRR), and Reporting Odds Ratio (ROR)-to assess the risk of drug-related AEs.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!